Close Menu

This story has been updated from a previous version to include information about the platorms on which Cepheid's test can be run.

NEW YORK – The US Food and Drug Administration on Friday issued Emergency Use Authorization for Cepheid's Xpert Xpress SARS-CoV-2 test for diagnosing COVID-19.

It is the first EUA for a SARS-CoV-2 that can be used at the point of care. In addition to high- and moderate-complexity laboratories, the rapid molecular test can be used in certain patient-care settings, the agency said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.